Annual CFI
-$108.39 M
-$165.40 M-290.14%
31 December 2023
Summary:
Spyre Therapeutics annual cash flow from investing activities is currently -$108.39 million, with the most recent change of -$165.40 million (-290.14%) on 31 December 2023. During the last 3 years, it has fallen by -$85.77 million (-379.21%). SYRE annual CFI is now -290.14% below its all-time high of $57.01 million, reached on 31 December 2022.SYRE Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$42.74 M
+$163.26 M+135.46%
30 September 2024
Summary:
Spyre Therapeutics quarterly cash flow from investing activities is currently $42.74 million, with the most recent change of +$163.26 million (+135.46%) on 30 September 2024. Over the past year, it has increased by +$78.01 million (+221.17%). SYRE quarterly CFI is now at all-time high.SYRE Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$218.01 M
+$140.37 M+39.17%
30 September 2024
Summary:
Spyre Therapeutics TTM cash flow from investing activities is currently -$218.01 million, with the most recent change of +$140.37 million (+39.17%) on 30 September 2024. Over the past year, it has dropped by -$109.62 million (-101.13%). SYRE TTM CFI is now -482.43% below its all-time high of $57.01 million, reached on 01 December 2022.SYRE TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SYRE Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +221.2% | -101.1% |
| 3 y3 years | -379.2% | +342.3% | -863.9% |
| 5 y5 years | -6133.1% | +313.9% | -10000.0% |
SYRE Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -290.1% | at low | at high | +135.5% | -482.4% | +39.2% |
| 5 y | 5 years | -290.1% | at low | at high | +135.5% | -482.4% | +39.2% |
| alltime | all time | -290.1% | at low | at high | +135.5% | -482.4% | +39.2% |
Spyre Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $42.74 M(-135.5%) | -$218.01 M(-39.2%) |
| June 2024 | - | -$120.52 M(+14.8%) | -$358.38 M(+55.1%) |
| Mar 2024 | - | -$104.96 M(+197.6%) | -$231.11 M(+113.2%) |
| Dec 2023 | -$108.39 M(-290.1%) | -$35.27 M(-63.9%) | -$108.39 M(+83.3%) |
| Sept 2023 | - | -$97.63 M(-1544.2%) | -$59.12 M(-207.5%) |
| June 2023 | - | $6.76 M(-61.9%) | $55.01 M(+12.3%) |
| Mar 2023 | - | $17.75 M(+26.8%) | $49.00 M(-14.0%) |
| Dec 2022 | $57.01 M(-352.0%) | - | - |
| Dec 2022 | - | $14.00 M(-15.1%) | $57.01 M(+8.2%) |
| Sept 2022 | - | $16.50 M(+2099.9%) | $52.67 M(+25.6%) |
| June 2022 | - | $750.00 K(-97.1%) | $41.95 M(-781.0%) |
| Mar 2022 | - | $25.76 M(+166.6%) | -$6.16 M(-72.8%) |
| Dec 2021 | -$22.62 M(+197.5%) | $9.66 M(+67.3%) | -$22.62 M(+517.7%) |
| Sept 2021 | - | $5.78 M(-112.2%) | -$3.66 M(+0.2%) |
| June 2021 | - | -$47.36 M(-609.2%) | -$3.65 M(-72.0%) |
| Mar 2021 | - | $9.30 M(-67.5%) | -$13.06 M(+71.7%) |
| Dec 2020 | -$7.60 M(+337.3%) | $28.62 M(+394.8%) | -$7.60 M(-70.6%) |
| Sept 2020 | - | $5.78 M(-110.2%) | -$25.90 M(+65.3%) |
| June 2020 | - | -$56.76 M(-484.7%) | -$15.67 M(+1599.6%) |
| Mar 2020 | - | $14.75 M(+42.9%) | -$922.00 K(-47.0%) |
| Dec 2019 | -$1.74 M | $10.33 M(-35.5%) | -$1.74 M(-87.8%) |
| Sept 2019 | - | $16.01 M(-138.1%) | -$14.20 M(-50.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | -$42.01 M(-401.5%) | -$28.81 M(+380.4%) |
| Mar 2019 | - | $13.94 M(-753.7%) | -$6.00 M(-60.6%) |
| Dec 2018 | -$15.23 M(-32.4%) | -$2.13 M(-252.4%) | -$15.23 M(+84.5%) |
| Sept 2018 | - | $1.40 M(-107.3%) | -$8.26 M(-48.2%) |
| June 2018 | - | -$19.20 M(-508.3%) | -$15.94 M(-304.8%) |
| Mar 2018 | - | $4.70 M(-2.9%) | $7.78 M(-134.6%) |
| Dec 2017 | -$22.53 M(+86.6%) | $4.84 M(-177.1%) | -$22.53 M(-9.2%) |
| Sept 2017 | - | -$6.29 M(-238.9%) | -$24.81 M(-26.6%) |
| June 2017 | - | $4.52 M(-117.7%) | -$33.82 M(-7.3%) |
| Mar 2017 | - | -$25.61 M(-1100.8%) | -$36.49 M(+202.2%) |
| Dec 2016 | -$12.08 M(+200.8%) | $2.56 M(-116.7%) | -$12.08 M(-20.3%) |
| Sept 2016 | - | -$15.29 M(-925.9%) | -$15.14 M(+357.6%) |
| June 2016 | - | $1.85 M(-255.4%) | -$3.31 M(-36.2%) |
| Mar 2016 | - | -$1.19 M(+133.7%) | -$5.19 M(+29.2%) |
| Dec 2015 | -$4.01 M(+1716.3%) | -$510.00 K(-85.3%) | -$4.01 M(+11.0%) |
| Sept 2015 | - | -$3.46 M(>+9900.0%) | -$3.62 M(+1485.5%) |
| June 2015 | - | -$24.00 K(+20.0%) | -$228.00 K(+9.1%) |
| Mar 2015 | - | -$20.00 K(-82.0%) | -$209.00 K(-5.4%) |
| Dec 2014 | -$221.00 K | -$111.00 K(+52.1%) | -$221.00 K(+100.9%) |
| Sept 2014 | - | -$73.00 K(+1360.0%) | -$110.00 K(+197.3%) |
| June 2014 | - | -$5000.00(-84.4%) | -$37.00 K(+15.6%) |
| Mar 2014 | - | -$32.00 K | -$32.00 K |
FAQ
- What is Spyre Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Spyre Therapeutics?
- What is Spyre Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Spyre Therapeutics?
- What is Spyre Therapeutics quarterly CFI year-on-year change?
- What is Spyre Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Spyre Therapeutics?
- What is Spyre Therapeutics TTM CFI year-on-year change?
What is Spyre Therapeutics annual cash flow from investing activities?
The current annual CFI of SYRE is -$108.39 M
What is the all time high annual CFI for Spyre Therapeutics?
Spyre Therapeutics all-time high annual cash flow from investing activities is $57.01 M
What is Spyre Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of SYRE is $42.74 M
What is the all time high quarterly CFI for Spyre Therapeutics?
Spyre Therapeutics all-time high quarterly cash flow from investing activities is $42.74 M
What is Spyre Therapeutics quarterly CFI year-on-year change?
Over the past year, SYRE quarterly cash flow from investing activities has changed by +$78.01 M (+221.17%)
What is Spyre Therapeutics TTM cash flow from investing activities?
The current TTM CFI of SYRE is -$218.01 M
What is the all time high TTM CFI for Spyre Therapeutics?
Spyre Therapeutics all-time high TTM cash flow from investing activities is $57.01 M
What is Spyre Therapeutics TTM CFI year-on-year change?
Over the past year, SYRE TTM cash flow from investing activities has changed by -$109.62 M (-101.13%)